Clinical trials: Hepatic Steatosis
Liver Steatoses, Liver Cirrhosis
Correlation of Ultrasound Based Measurements of Liver Stiffness and Steatosis With MRI
The investigators will assess the ability of ultrasound (US) to measure liver stiffness (cirrhosis) and liver fat content (steatosis).
- Trial name
- NCT03342703
- Testing
- Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Non-alcoholic Fatty Liver Disease, Morbid Obesity
Ursodeoxycholic Acid in Bariatric Surgery
In an open-label trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery will be administered 20 mg/kg/day ursodeoxycholic acid for three weeks until the day before surgery.
- Trial name
- NCT01548079
- Testing
- Ursodeoxycholic Acid (UDCA)
- Volunteers
- 40 people
- Sponsor
- Sahlgrenska University Hospital
Fatty Liver, Acute Ischemic Cerebral Stroke
Burden Fatty Liver Among Acute Ischemic Cerebral Stroke Patients
1. Assess frequency of hepatic steatosis among patients in patients with Ischemic stroke without previous risk factors 2. Assess outcomes morbidity and mortality ischemic stroke in correlation with hepatic steatosis .
- Trial name
- NCT06628700
- Volunteers
- 97 people
- Sponsor
- Assiut University
Hepatic Fat Accumulation, Nonalcoholic Fatty Liver Disease
Dietary Protein and Hepatic Fat Accumulation
The objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.
- Trial name
- LiF-Pro (NCT01354626)
- Testing
- dietary protein, low-protein
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriatic Arthritis (PsA), Liver Fibrosis
Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments
Psoriatic arthritis (PsA) is an inflammatory joint disease that can also affect the liver. Some medications used to treat PsA, such as biological agents (TNF-alpha inhibitors and IL-17 inhibitors), may influence liver health over…
- Conditions
- Psoriatic Arthritis (PsA), Liver Fibrosis, Liver Diseases
- Trial name
- FIB-4 PsA (NCT06918886)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Bezmialem Vakif University